Risk Factors Update Summary

• Plans to utilize external ABPS and PCI facilities for DAXXIFY® production, facing risks of facility damage or disruption.
• Introduced new pricing for DAXXIFY ®, generating $95.0 million in revenue since September 2022.
• Discussed risks related to manufacturing, including the need for reliable forecasting and sourcing of DAXXIFY ®.
• Changes in legislative and regulatory healthcare reforms could significantly affect reimbursement and business operations.
• Increased pricing pressures due to managed healthcare trends and legislative changes may impact product profitability.
• Added advance notice procedures for stockholders in bylaws to nominate directors at meetings.
• Lack of earthquake insurance and limited disaster recovery plans could lead to substantial expenses.
• Announced approval of DAXXIFY ® for cervical dystonia, the first therapeutics indication.
• Emphasized the need to obtain adequate and timely supply of DAXXIFY ® and RHA ® Collection of dermal fillers.
• Announced a plan to exit the Fintech Platform business to reallocate capital.
• Increased scrutiny on compliance with anti-bribery laws and regulations, impacting business operations and reputation.
• Delays in clinical trials and uncertainty in achieving regulatory objectives may impact financial results.
• Limited experience in commercializing therapeutics products, particularly DAXXIFY ® for cervical dystonia.
• Highlighted the importance of establishing and maintaining relationships with injectors and HCPs.
• Specified requirements for stockholder nominations under Rule 14a-19(b) under the Exchange Act.
• Failure to comply with data privacy laws may result in significant liability and harm business reputation.
• Provisions may discourage potential acquirers from soliciting proxies or attempting control of the company.